Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes serious adverse events compared with standard regimen (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in serious adverse events compared with standard regimen (low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
The intervention may leads to higher serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · Children and adults with blood smear positive P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review